In has been recently revealed that Apex Biosciences and Slyngshot Health have officially completed their merger to become The Anthos Group. The merger is anticipated to lead the duo, now one, to disrupt the hemp and cannabis industry as reported by PR Web.
According to the claims made, Apex Biosciences garnered attention from Slyngshot Health as a result of its agricultural programs and the number of inspections that they have since passed in serving in compliance with regulatory frameworks.
Although Slyngshot Health is renowned for its work in the medical sector with great focus on technology, education and “Personalized Medicine,” the need to further understand cannabidiol is said to be the reason for such a merger.
CEO of The Anthos Group, Badal Shah noticed the opportunity that existed amidst the cannabis industry, in which many launched products lacked quality, adding that many seems to have housed “different contaminants”. With the aim of tending to patients with high-quality solutions comes The Anthos Group.
The President of The Anthos Group, Shan Umer expressed a similar sentiment to that of Shah, adding that quality comes from “focusing on the pure science of cultivation.” With organic products serving as the newly formed firm’s foundation, the team plans to launch product lines infused with CBD including the likes of cosmetics, medical, lifestyle and fitness segments.